Tesla Motors Inc (TSLA) 227.75 $TSLA Would the U.S.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tesla Motors Inc (TSLA) 227.75 $TSLA

Would the U.S. Government Ever Let Tesla Motors Fail?
Evan Niu, CFA, The Motley Fool - Motley Fool - Fri Mar 25, 9:00AM CDT
Tesla service center. Image source: Tesla. With the U.S. auto market recently setting a fresh record in annual new car sales, and Tesla Motors likewise setting its own quarterly delivery record, this might be a strange time to ask whether or not...
TSLA: 227.75 (+5.17), GM: 30.96 (-0.35)

Tesla Motors, Inc.'s Model 3 Unveil Is Just a Week Away: Will Reservations Soar?
Daniel Sparks, The Motley Fool - Motley Fool - Thu Mar 24, 2:31PM CDT
Ahead of electric-car maker Tesla Motors ' event next week to unveil its lowest cost model yet, little is known about the super secret car. Big questions about its design and features remain unanswered. But investors are interested in more than...
TSLA: 227.75 (+5.17)

Tesla Driving Author Offers Green Energy Plays
at The Street - Thu Mar 24, 2:12PM CDT
It's a matter of demographics, said Gianni Kovacevic, author of 'My Electrician Drives a Porsche?'
TSLA: 227.75 (+5.17)

Auto Stock Roundup: Toyota's Auto Braking Plans, Ford & Honda's Plant Investments
Zacks Equity Research - Zacks Investment Research - Thu Mar 24, 8:18AM CDT
Toyota (TM) plans to make automatic braking a standard feature on most new vehicles in the U.S. by 2017. Ford (F) & Honda (HMC) announced new investments in plants.
TSLA: 227.75 (+5.17), F: 13.06 (-0.20), WGO: 21.31 (+0.75), THO: 61.62 (+0.41), AZO: 803.06 (-2.23), TM: 106.32 (-1.78), HMC: 26.69 (-0.35)

Tesla's Model 3 Is Coming -- Here's How to Order It
at The Street - Thu Mar 24, 7:01AM CDT
Tesla is slated to unveil its latest vehicle, the Model 3, later this month. Ordering one right off the bat, however, can be a tricky task.
TSLA: 227.75 (+5.17)

Why Tesla’s Switching Its Powerwall Plans — Tech Roundup
at The Street - Wed Mar 23, 3:46PM CDT
Tesla's changing its Powerwall plans, streaming music revenue overtake music download revenue and eMarketer sees a double-digit decline in ad revenue for struggling Yahoo!.
YHOO: 34.86 (+0.06), TSLA: 227.75 (+5.17), P: 10.93 (+1.05), FB: 113.05 (+0.51), GOOGL: 754.84 (-2.72), TWTR: 15.91 (-0.10), AAPL: 105.67 (-0.46)

Why Tesla (TSLA) Stock Is Tumbling Today
at The Street - Wed Mar 23, 2:33PM CDT
Tesla (TSLA) stock is down this afternoon after S&P Global Market Intelligence cut the 'volatile' shares to 'sell.'
TSLA: 227.75 (+5.17)

NVIDIA's Automotive Business: 3 Numbers You Need to Know
Chris Neiger, The Motley Fool - Motley Fool - Wed Mar 23, 12:15PM CDT
Image source: NVIDIA. NVIDIA 's not exactly the first company to come to mind when investors think about investing in the automotive industry, but it should be. The chipmaker is driving further into the the infotainment space with its Tegra...
TSLA: 227.75 (+5.17), IHS: 119.57 (-1.43), HMC: 26.69 (-0.35), NVDA: 34.48 (+0.05)

Tesla Is Overdue for a Pullback
at The Street - Wed Mar 23, 6:11AM CDT
Tesla is extremely overbought and gearing up for a pullback, which should lead to lower-risk buying opportunities.
TSLA: 227.75 (+5.17)

Another Important Benefit of Tesla's Direct Sales Model
Evan Niu, CFA, The Motley Fool - Motley Fool - Tue Mar 22, 6:00PM CDT
Tesla owns the sales and service experiences, building a relationship with the customer. Image source: Tesla. When was the last time you called your car company? It's a deceptively simple question, but it also underscores an important benefit of ...
TSLA: 227.75 (+5.17), GM: 30.96 (-0.35)

Can General Motors Compete in Driverless Cars?
Chris Neiger, The Motley Fool - Motley Fool - Tue Mar 22, 2:00PM CDT
GM's Jeremy Salinger lets Super Cruise take the wheel. Source: GM. Let's be clear about one thing: General Motors is ahead of many carmakers in the driverless car space. Nearly every automaker has an autonomous driving game plan, but GM's has...
TSLA: 227.75 (+5.17), F: 13.06 (-0.20), GM: 30.96 (-0.35), GOOGL: 754.84 (-2.72), GOOG: 735.30 (-2.76)

Tesla (TSLA) Reveals Model 3 Reservation and Delivery Plans
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 1:10PM CDT
In the run-up to the unveiling of Model 3, scheduled for Mar 31, Tesla Motors, Inc. (TSLA) has revealed details of its reservation and delivery plans.
TSLA: 227.75 (+5.17), GT: 32.18 (-0.03), CTB: 36.00 (-0.59), NAV: 12.24 (+0.10)

Zipcar co-founder Robin Chase talks collaborative economy at Discovery 2016
CNW Group - Tue Mar 22, 11:08AM CDT
Transportation entrepreneur Robin Chase, co-founder and former CEO of Zipcar, the world's largest car-sharing service, will bring her themes of the collaborative economy and the new face of capitalism to Ontario Centres of Excellence's Discovery 2016.
TSLA: 227.75 (+5.17)

The Future of Batteries and Electric Vehicles
Tyler Crowe, The Motley Fool - Motley Fool - Tue Mar 22, 7:34AM CDT
Electric cars have been on the horizon for years now, but what will it actually take for a majority of the world's vehicles to be powered by batteries instead of combustion engines? In this week's Industry Focus: Energy , Tyler Crowe interviews...
TSLA: 227.75 (+5.17), F: 13.06 (-0.20), GM: 30.96 (-0.35), GOOGL: 754.84 (-2.72), GOOG: 735.30 (-2.76), AAPL: 105.67 (-0.46)

Devonshire Research Group Announces the Issuance of Tesla's Intellectual Property Research Analysis
Marketwired - Tue Mar 22, 7:30AM CDT
On Tuesday, March 22nd, Devonshire Research Group issued a research presentation that provides in-depth analysis of Tesla's technology and intellectual property. The presentation, entitled "Tesla Motors," is a result of extensive engineering analysis and is based on months of research. The presentation can be found on Devonshire Research Group's website at www.devonshireresearch.com
TSLA: 227.75 (+5.17)

Upgrade Alert for Tesla Motors Inc (TSLA)
Comtex SmarTrend(R) - Tue Mar 22, 3:05AM CDT
Tesla Motors Inc (NASDAQ:TSLA) was upgraded from Hold to Buy at Argus Research today. The stock closed yesterday at $238.32 on volume of 5.3 million shares, below average daily volume of 5.7 million. Potential upside of 23.4% exists for Tesla Motors Inc, based on a current level of $238.32 and analysts' average consensus price target of $294.07. Tesla Motors Inc shares have support at the 200-day moving average (MA) of $228.86 and additional support at the 50-day MA of $191.04.
TSLA: 227.75 (+5.17)

Shares of TSLA Up 41.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 22, 1:15AM CDT
SmarTrend identified an Uptrend for Tesla Motors Inc (NASDAQ:TSLA) on February 18th, 2016 at $168.86. In approximately 1 month, Tesla Motors Inc has returned 41.13% as of today's recent price of $238.32.
TSLA: 227.75 (+5.17)

Energy Storage in India? General Electric Goes for Growth
Justin Loiseau, The Motley Fool - Motley Fool - Mon Mar 21, 2:44PM CDT
Image source: General Electric Company.  Tesla Motors may be overlooking the biggest market for its energy storage solution. While Elon Musk is pushing PowerWalls in the U.S., General Electric is exploring gigantic growth opportunities in...
TSLA: 227.75 (+5.17), GE: 31.11 (+0.04)

Can Baidu Develop a Driverless Car By 2018?
Andrew Tonner, The Motley Fool - Motley Fool - Mon Mar 21, 12:19PM CDT
Image source: Google. In case you hadn't noticed, there's something of an arms race currently under way in the automotive industry. The ongoing battle for the very future of how people and goods move from place to place will fundamentally...
TSLA: 227.75 (+5.17), BIDU: 184.86 (+1.02), GOOGL: 754.84 (-2.72), GOOG: 735.30 (-2.76), AAPL: 105.67 (-0.46)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
More News Articles